News & Videos - Stocks - English

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance PR Newswire INDIANAPOLIS, Dec. 8, 2019 INDIANAPOLIS , Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced interim clinical data...

Bristol-Myers Squibb Company (NYSE: BMY) today announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed CAR T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells, were presented during the 2019 ASH Annual Meeting in Orlando, Fla. These studies included an evaluation of liso-cel in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (TRANSCEND CLL 004); a...

Dominion Energy Ohio Issues Scammer Alert to Customers PR Newswire CLEVELAND, Dec. 8, 2019 CLEVELAND , Dec. 8, 2019 /PRNewswire/ -- Dominion Energy Ohio warns customers not to provide banking or other personal information to scammers who claim such data is required to receive a new federal tax cut credit. The company reminds customers they will begin receiving those credits automatically, beginning in April 2020 , in their monthly bills. On December 4 , the Public Utilities Commission of Ohio...

RM LAW Announces Class Action Lawsuit Against Grubhub Inc. PR Newswire BERWYN, Pa., Dec. 8, 2019 BERWYN, Pa. , Dec. 8, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Grubhub Inc. ("Grubhub" or the "Company") (NYSE: GRUB) common stock between July 30, 2019 and October 28, 2019 , inclusive (the "Class Period"). Grubhub shareholders may, no later than January 21, 2020 , move the Court for appointment as a...

RM LAW Announces Class Action Lawsuit Against The RealReal, Inc. PR Newswire BERWYN, Pa., Dec. 8, 2019 BERWYN, Pa. , Dec. 8, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased The RealReal, Inc. ("RealReal" or the "Company") (NASDAQ: REAL) securities pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's June...

~ Sustained FIX Activity at Therapeutic Levels 1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for Immunosuppression in One Year Following Dosing with Etranacogene Dezaparvovec ~ ~ Long-term Clinical Benefit and Tolerability of AMT-060 Maintained in All Patients Through up to 4 Years of Follow-Up ~ ~ Investor Webcast on Monday, December 9, 2019 at 7:00 a.m. EST ~ LEXINGTON, Mass. and AMSTERDAM, the...

RM LAW Announces Class Action Lawsuit Against Prudential Financial, Inc. PR Newswire BERWYN, Pa., Dec. 8, 2019 BERWYN, Pa. , Dec. 8, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Prudential Financial, Inc. ("Prudential" or the "Company") (NYSE: PRU) securities between February 15, 2019 and August 2, 2019 , inclusive (the "Class Period"). Prudential shareholders may, no later than January 27, 2020 , move...

MONTRÉAL, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Alliance Forêt Boréale, Ville de Dolbeau-Mistassini, Hebdos Québec, Métro Média as well as unions representing employees of TC Transcontinental (TSX: TCL.A TCL.B), namely the Centrale des syndicats démocratiques (CSD), the Syndicat des travailleurs industriels et commerciaux (STIC) and the Syndicat des Teamsters, are standing together with TC Transcontinental to avoid the disappearance of Publisac and the collapse of the socioeconomic system...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zendesk, Inc. (NYSE: ZEN) between February 6, 2019 and October 1, 2019 (the “Class Period”) of the important December 23, 2019 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Zendesk investors under the federal securities laws. To join the Zendesk class action, go to http://www.rosenlegal.com/cases-register-1698.html or call Phillip Kim, Esq. toll-free at...

NET 1 LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Net 1 UEPS Technologies, Inc. - UEPS PR Newswire NEW YORK, Dec. 8, 2019 NEW YORK , Dec. 8, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) between September 12, 2018 and November 8, 2018 , inclusive (the "Class Period"). The lawsuit seeks to...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that updated results from SPiReL, an ongoing Phase 2 investigator-sponsored study of DPX-Survivac in combination with pembrolizumab in patients with recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL), were presented in a poster session at the 61 st American Society of Hematology (ASH) Annual Meeting in Orlando, FL. The poster, which included...

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies - Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL - - 52% Overall Response Rate Observed in Patients with AITL - - Rapid and Significant Reduction in Itch Among Patients with CTCL - PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 SOUTH SAN FRANCISCO, Calif. ,...

Company Announcement No. 17 Aalborg, 8. December 2019 Seluxit signs an agreement with a new client within in the healthcare industry Seluxit is pleased to announce an upcoming collaboration with a Danish company within the healthcare industry, which currently wishes to remain anonymous. The collaboration will enable IoT Fleet Management of current medical devices. Seluxit will develop the solution using its standard hardware and software components and the Seluxit cloud based IoT platform. CEO,...

Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 PR Newswire STOCKHOLM, Dec. 8, 2019 STOCKHOLM , Dec. 8, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or...

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL patients dosed with AUTO3 Investor call to be held December 9 at 8:30 am ET / 1:30 pm GMT to review data LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL) announced today new data highlighting progress on AUTO3, the first-in-human bicistronic CD19 and CD22 CAR, in...

MARSEILLE, France, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine. The final analysis showed that...

First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma PR Newswire TARRYTOWN, N.Y., Dec. 8, 2019 TARRYTOWN, N.Y. , Dec. 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. REGN5458 is...

Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested -- Plan to initiate screening in registration-enabling portion of PIONEER trial in indolent SM in first half 2020 -- -- Top-line EXPLORER trial data in advanced SM support planned NDA submission in Q1 2020 -- -- Blueprint Medicines to host investor event and webcast on Sunday, December 8, 2019 at 8:30 p.m. ET -- PR...

Results from a Survey With Patients With Immune Thrombocytopenia (ITP) Demonstrates Disease Burden and Impact for Patients With ITP PR Newswire STOCKHOLM, Dec. 8, 2019 STOCKHOLM , Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease burden and impact for patients with immune thrombocytopenia (ITP), at the 61st Annual Meeting of the American Society of Hematology...

DNI Metals Inc. (DNI: CSE; DNMKF: OTC) ("DNI" or the "Company") On September 24, 2018 a Settlement Agreement (the “ Agreement ”) was reached after arbitration between DNI and Cougar Metals NL (“ Cougar ”) in regards to the Cougar earn-in to Vohitsara, DNI’s graphite project in Madagascar. On July 23, 2019, DNI issued Cougar a default notice claiming that Cougar had breached the non-disparagement provision in the Agreement. Cougar requested an arbitration to dispute the default. A...